TECENTRIQ is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Genentech, Inc.. The primary component is Atezolizumab.
| Product ID | 50242-917_0db9ee06-7a81-45f8-862b-b84180b9db13 |
| NDC | 50242-917 |
| Product Type | Human Prescription Drug |
| Proprietary Name | TECENTRIQ |
| Generic Name | Atezolizumab |
| Dosage Form | Injection, Solution |
| Route of Administration | INTRAVENOUS |
| Marketing Start Date | 2016-05-18 |
| Marketing Category | BLA / BLA |
| Application Number | BLA761034 |
| Labeler Name | Genentech, Inc. |
| Substance Name | ATEZOLIZUMAB |
| Active Ingredient Strength | 1200 mg/20mL |
| Pharm Classes | Programmed Death Receptor-1 Blocking Antibody [EPC],Antibodies, Monoclonal, Humanized [CS],Antibodies, Monoclonal [CS],Antibodies [CS],Programmed Death Receptor-1-directed Antibody Interactions [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2022-12-31 |
| Marketing Start Date | 2016-05-18 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | BLA |
| Application Number | BLA761034 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2016-08-11 |
| Marketing Category | BLA |
| Application Number | BLA761034 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2016-05-18 |
| Ingredient | Strength |
|---|---|
| ATEZOLIZUMAB | 1200 mg/20mL |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 50242-917 | TECENTRIQ | atezolizumab |
| 50242-918 | TECENTRIQ | atezolizumab |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() TECENTRIQ 86441478 5027722 Live/Registered |
GENENTECH, INC. 2014-10-31 |